Cellular Physiology and molecular biology of amylin in NIDDM
Cellular Physiology and molecular biology of amylin in NIDDM
批准号:
07457226
负责人:
MATSUKURA Shigeru
金额:
$4.22万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
1995
资助国家:
日本
项目状态:
已结题
起止时间:
1995 至 1996
中文摘要
胰淀素,也称为胰岛淀粉样多肽,是1987年从胰岛淀粉样蛋白中分离的37个氨基酸的肽。该肽被认为通过对抗外周组织中的胰岛素作用和通过淀粉样蛋白沉积破坏胰岛结构而参与NIDDM的病因学。我们研究了胰淀素的性质、糖耐量异常时胰淀素的合成和分泌以及NIDDM时胰岛淀粉样蛋白的形成。我们开发了三种胰淀素的RIA:人和大鼠胰淀素的共同N端区域,以及人和大鼠胰淀素的C端区域。我们还鉴定了胰淀素在许多哺乳动物的胰腺、胃肠道和血浆中的内源性分子形式。胰淀素信使RNA主要在胰腺中表达,其大小为900个碱基。在大鼠胚胎胰腺中检测到胰淀素,其含量在发育过程中逐渐增加。出生后第3天胃窦中出现胰淀素。在人类胰腺中,胰淀素在妊娠15周时被检测到。人胰淀素含量为221.6 <plus-minus>± 78.2 pmol/g湿重,大鼠胰淀素含量为328.5 <plus-minus>± 25.0 pmol/g湿重,约为胰岛素含量的1-2%。正常人基础血浆免疫反应胰淀素水平为2.4- 5.8fmol/ml,在肥胖或糖耐量受损的受试者中升高,而在糖尿病患者中降低。胰岛淀粉样蛋白沉积不是NIDDM的主要病因,但淀粉样蛋白沉积可加重胰岛功能障碍,促进NIDDM的进展。
英文摘要
Amylin, also designated islet amyloid polypeptide, is a 37-amino acid peptide that was isolated from islet amyloid in 1987. The peptide is thought to be involved in the etiology of NIDDM by opposing insulin action in peripheral tissues and by destroying islet construction through amyloid deposition. We studied the properties of amylin, its synthesis and secretion in abnormal glucose tolerance, and amyloidogenesis of the islet in NIDDM.We developed three RIAs for amylin : human and rat common N-terminal region of amylin, and both human and rat C-terminal amylin. We also identified endogenous molecular forms of amylin in pancreata, gastrointestinal tracts and plasma of many mammals. Amylin messenger RNA whose size is 900 bases is predminantly expressed in the pancreas. Amylin is detected in rat fetal pancreas, and its content gradually increases during development. Amylin in the antrum appears 3 days after birth. In the human pancreas, amylin is detected at 15 weeks of gestation. Pancreatic amylin content was 221.6<plus-minus>78.2 pmol/g wet weight in man and 328.5<plus-minus>25.0 pmol/g wet weight in rat, being approximately 1-2% of insulin content. Basal plasma immunoreactive amylin level in normal individuals was 2.4-5.8 fmol/ml, being increased in subjects with ovesity or impaired glucose tolerance, and decreased in diabetic patients. Amylin was co-secreted with insulin in physiological conditiIslet amyloid deposition is not responsible for the primary etiology of NIDDM,however, the amyloid deposits could intensify islet dysfunction and contribute to the progression of NIDDM.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
H.Nakazato,S.Matsukura: "Proceeding on International workshop on Amylin Assay Methodology" Amylin Pharmacluticals, 402 (1996)
H.Nakazato,S.Matsukura:“Amylin 测定方法国际研讨会进展”Amylin Pharmacluticals,402 (1996)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
miyazato,m.,Nakazato,m.Shiomi,K.,Kangawa,K,matsuo,H,matsukura,S.: "Isolation and sequence determination of two novel N-terminal fragments of islet amyloid peptide in rat pancreas" Regul.Pept.49. 203-210 (1994)
miyazato,m.,Nakazato,m.Shiomi,K.,Kangawa,K,matsuo,H,matsukura,S.:“大鼠胰腺中胰岛淀粉样肽的两个新型 N 末端片段的分离和序列测定”Regul.Pept
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
中里雅光,松倉茂: "アミリンの遺伝子構造とII型糖尿病の成因における病態生理学的意義" 病理と臨床. 14. 1474-1479 (1996)
Masamitsu Nakazato,Shigeru Matsukura:“胰淀素的遗传结构及其在 II 型糖尿病发病机制中的病理生理学意义”《病理学与临床》14。1474-1479 (1996)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
宮里 幹也、中里雅光、松倉 茂: "糖尿病とアミロイド" BIO Clinica. 9. 36-40 (1994)
Mikiya Miyazato、Masamitsu Nakazato、Shigeru Matsukura:“糖尿病和淀粉样蛋白”BIO Clinica。 9. 36-40 (1994)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
塩見一剛、中里雅光、松倉 茂、松尾壽之: "老化と生理活性ペプチド,Advances in Aging and Health Research" 長寿科学振興財団, 11 (1994)
Kazutoshi Shiomi、Masamitsu Nakazato、Shigeru Matsukura、Toshiyuki Matsuo:“衰老和生物活性肽,衰老和健康研究的进展”长寿科学促进基金会,11(1994)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 8 条
Uroguanylin in the pathophysiological mechanism in water and electrolyte homeostoses
-
批准号:10670489
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.05万
-
财政年份:1998
-
负责人:MATSUKURA Shigeru
-
依托单位:
Pathophysiological Significance of IAPP in NIDDM
-
批准号:03671159
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.34万
-
财政年份:1991
-
负责人:MATSUKURA Shigeru
-
依托单位:
国内基金
海外基金
IAPP在伴糖尿病的阿尔兹海默病发生发展中的分子机制
-
批准号:81771177
-
项目类别:面上项目
-
资助金额:54.0万元
-
批准年份:2017
-
负责人:周华东
-
依托单位:
IAPP对钙调控胰岛素分泌的影响及其在β细胞功能减退中的作用研究
-
批准号:81241030
-
项目类别:专项基金项目
-
资助金额:10.0万元
-
批准年份:2012
-
负责人:朱铁虹
-
依托单位: